These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34292177)

  • 1. Mast cell activation syndrome: is anaphylaxis part of the phenotype? A systematic review.
    Sabato V; Michel M; Blank U; Ebo DG; Vitte J
    Curr Opin Allergy Clin Immunol; 2021 Oct; 21(5):426-434. PubMed ID: 34292177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low Prevalence of Idiopathic Mast Cell Activation Syndrome Among 703 Patients With Suspected Mast Cell Disorders.
    Zaghmout T; Maclachlan L; Bedi N; Gülen T
    J Allergy Clin Immunol Pract; 2024 Mar; 12(3):753-761. PubMed ID: 38056692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Using the Right Criteria for MCAS.
    Gulen T
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):39-51. PubMed ID: 38243020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mast Cell Activation Syndromes: Collegium Internationale Allergologicum Update 2022.
    Valent P; Hartmann K; Bonadonna P; Niedoszytko M; Triggiani M; Arock M; Brockow K
    Int Arch Allergy Immunol; 2022; 183(7):693-705. PubMed ID: 35605594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mast cell activation syndrome: Myths and realities.
    Zhang S; Bernstein JA
    Allergy Asthma Proc; 2021 May; 42(3):198-204. PubMed ID: 33980332
    [No Abstract]   [Full Text] [Related]  

  • 6. Selecting the Right Criteria and Proper Classification to Diagnose Mast Cell Activation Syndromes: A Critical Review.
    Gülen T; Akin C; Bonadonna P; Siebenhaar F; Broesby-Olsen S; Brockow K; Niedoszytko M; Nedoszytko B; Oude Elberink HNG; Butterfield JH; Sperr WR; Alvarez-Twose I; Horny HP; Sotlar K; Schwaab J; Jawhar M; Zanotti R; Nilsson G; Lyons JJ; Carter MC; George TI; Hermine O; Gotlib J; Orfao A; Triggiani M; Reiter A; Hartmann K; Castells M; Arock M; Schwartz LB; Metcalfe DD; Valent P
    J Allergy Clin Immunol Pract; 2021 Nov; 9(11):3918-3928. PubMed ID: 34166845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of the TPSAB1 genotype in mast cell diseases: A REMA study in a cohort of 959 individuals.
    González-de-Olano D; Navarro-Navarro P; Muñoz-González JI; Sánchez-Muñoz L; Henriques A; de-Andrés-Martín A; Peralta-Arjonilla D; Mayado A; Jara-Acevedo M; García-Montero AC; Orfao A; Álvarez-Twose I
    Allergy; 2024 Mar; 79(3):711-723. PubMed ID: 37818990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Puzzling Mast Cell Trilogy: Anaphylaxis, MCAS, and Mastocytosis.
    Gülen T
    Diagnostics (Basel); 2023 Oct; 13(21):. PubMed ID: 37958203
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mast Cell-Targeting Therapies in Mast Cell Activation Syndromes.
    Sabato V; Beyens M; Toscano A; Van Gasse A; Ebo DG
    Curr Allergy Asthma Rep; 2024 Feb; 24(2):63-71. PubMed ID: 38217824
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
    Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mast cell corticotropin-releasing factor subtype 2 suppresses mast cell degranulation and limits the severity of anaphylaxis and stress-induced intestinal permeability.
    D'Costa S; Ayyadurai S; Gibson AJ; Mackey E; Rajput M; Sommerville LJ; Wilson N; Li Y; Kubat E; Kumar A; Subramanian H; Bhargava A; Moeser AJ
    J Allergy Clin Immunol; 2019 May; 143(5):1865-1877.e4. PubMed ID: 30439403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Update on idiopathic anaphylaxis.
    Calvani M
    Pediatr Allergy Immunol; 2022 Jan; 33 Suppl 27():52-53. PubMed ID: 35080312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mast cell activation syndromes presenting as anaphylaxis.
    Akin C
    Immunol Allergy Clin North Am; 2015 May; 35(2):277-85. PubMed ID: 25841551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathogenic and diagnostic relevance of KIT in primary mast cell activation disorders.
    Muñoz-González JI; García-Montero AC; Orfao A; Álvarez-Twose I
    Ann Allergy Asthma Immunol; 2021 Oct; 127(4):427-434. PubMed ID: 34298172
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How to diagnose mast cell activation syndrome: practical considerations.
    Romantowski J; Górska A; Lange M; Nedoszytko B; Gruchała-Niedoszytko M; Niedoszytko M
    Pol Arch Intern Med; 2020 Apr; 130(4):317-323. PubMed ID: 32096778
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Defining hereditary alpha-tryptasemia as a risk/modifying factor for anaphylaxis: are we there yet?
    Couto ML; Silva M; Barbosa MJ; Ferreira F; Fragoso AS; Azenha Rama T
    Eur Ann Allergy Clin Immunol; 2023 Jul; 55(4):152-160. PubMed ID: 36927821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
    Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME;
    J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why the 20% + 2 Tryptase Formula Is a Diagnostic Gold Standard for Severe Systemic Mast Cell Activation and Mast Cell Activation Syndrome.
    Valent P; Bonadonna P; Hartmann K; Broesby-Olsen S; Brockow K; Butterfield JH; Triggiani M; Lyons JJ; Oude Elberink JNG; Arock M; Metcalfe DD; Akin C
    Int Arch Allergy Immunol; 2019; 180(1):44-51. PubMed ID: 31256161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaphylaxis and Mast Cell Disorders.
    Gülen T; Akin C
    Immunol Allergy Clin North Am; 2022 Feb; 42(1):45-63. PubMed ID: 34823750
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
    Giannetti MP; Akin C; Hufdhi R; Hamilton MJ; Weller E; van Anrooij B; Lyons JJ; Hornick JL; Pinkus G; Castells M; Pozdnyakova O
    J Allergy Clin Immunol; 2021 Apr; 147(4):1497-1501.e1. PubMed ID: 33248113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.